Sponsor:
Mark Pimentel, MD
Code:
NCT06727422
Conditions
IBS (Irritable Bowel Syndrome)
IBS-D (Diarrhea-predominant)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
rifaximin 66mg + N-acetylcysteine 560mg three times daily
RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
Placebo
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-10. This information was provided to ClinicalTrials.gov by Mark Pimentel, MD on 2026-04-20.